Lauriane Eberst

1.0k total citations
38 papers, 415 citations indexed

About

Lauriane Eberst is a scholar working on Oncology, Reproductive Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Lauriane Eberst has authored 38 papers receiving a total of 415 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 11 papers in Reproductive Medicine and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Lauriane Eberst's work include Ovarian cancer diagnosis and treatment (11 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Pancreatic and Hepatic Oncology Research (5 papers). Lauriane Eberst is often cited by papers focused on Ovarian cancer diagnosis and treatment (11 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Pancreatic and Hepatic Oncology Research (5 papers). Lauriane Eberst collaborates with scholars based in France, Italy and United States. Lauriane Eberst's co-authors include Caroline Bailleux, Thomas Bachelot, Philippe A. Cassier, David Pérol, Isabelle Treilleux, C. Terret, Mehdi Brahmi, Christophe Caux, Christine Ménétrier‐Caux and Sylvie Chabaud and has published in prestigious journals such as Journal of Clinical Oncology, Oncogene and Scientific Reports.

In The Last Decade

Lauriane Eberst

35 papers receiving 409 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lauriane Eberst France 10 215 164 88 82 50 38 415
B Marmey France 6 149 0.7× 138 0.8× 103 1.2× 54 0.7× 9 0.2× 6 340
Irmgard Kronberger Austria 8 114 0.5× 196 1.2× 75 0.9× 55 0.7× 38 0.8× 15 427
Kyriaki Pliarchopoulou Greece 10 160 0.7× 90 0.5× 141 1.6× 39 0.5× 17 0.3× 14 351
Kanae Nosaka Japan 12 153 0.7× 135 0.8× 178 2.0× 29 0.4× 54 1.1× 36 425
K. Boye France 7 154 0.7× 77 0.5× 61 0.7× 81 1.0× 29 0.6× 8 316
James Dean United Kingdom 8 111 0.5× 134 0.8× 212 2.4× 103 1.3× 30 0.6× 24 505
Huiqiang Huang China 11 236 1.1× 55 0.3× 60 0.7× 145 1.8× 17 0.3× 27 389
Séverine Tabone‐Eglinger France 12 83 0.4× 209 1.3× 74 0.8× 99 1.2× 27 0.5× 28 446
Peter Houghton United States 8 150 0.7× 165 1.0× 171 1.9× 42 0.5× 23 0.5× 20 400
Vanessa Vanspauwen Belgium 9 96 0.4× 229 1.4× 82 0.9× 12 0.1× 62 1.2× 13 333

Countries citing papers authored by Lauriane Eberst

Since Specialization
Citations

This map shows the geographic impact of Lauriane Eberst's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lauriane Eberst with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lauriane Eberst more than expected).

Fields of papers citing papers by Lauriane Eberst

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lauriane Eberst. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lauriane Eberst. The network helps show where Lauriane Eberst may publish in the future.

Co-authorship network of co-authors of Lauriane Eberst

This figure shows the co-authorship network connecting the top 25 collaborators of Lauriane Eberst. A scholar is included among the top collaborators of Lauriane Eberst based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lauriane Eberst. Lauriane Eberst is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zemmour, Christophe, Manuel Rodrigues, Isabelle Ray‐Coquard, et al.. (2025). PARP inhibitors as maintenance therapy in ovarian cancer after platinum-sensitive recurrence: real-world experience from the Unicancer network. The Oncologist. 30(5).
2.
3.
Gomez‐Roca, Carlos, Sylvie Chabaud, Céline Rodriguez, et al.. (2024). The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers. Science Translational Medicine. 16(731). eadd1834–eadd1834. 32 indexed citations
4.
Terret, C., Camille Schiffler, Hélène Vanacker, et al.. (2024). Xevinapant Combined with Pembrolizumab in Patients with Advanced, Pretreated, Colorectal and Pancreatic Cancer: Results of the Phase Ib/II CATRIPCA Trial. Clinical Cancer Research. 30(10). 2111–2120. 3 indexed citations
5.
Banda, Kondwani Joseph, et al.. (2024). 748P Phase II dose optimization with EZH2/EZH1 inhibitor tulmimetostat in patients with ARID1A-mutated ovarian clear cell carcinoma. Annals of Oncology. 35. S567–S568. 1 indexed citations
6.
Tourneau, Christophe Le, Frédéric Rolland, Olivier Capitain, et al.. (2023). Immunogenicity and clinical activity of tipapkinogen sovacivec (TG4001), an HPV-16 cancer vaccine: A randomized phase 2 study in advanced anogenital cancers.. Journal of Clinical Oncology. 41(16_suppl). 2630–2630.
7.
Rodrigues, Manuel, Lauriane Eberst, Philippe Follana, et al.. (2023). Real-world dostarlimab use in advanced/recurrent endometrial cancer in France. Bulletin du Cancer. 110(10). 1041–1050. 1 indexed citations
8.
Azaïs, Henri, Lise Lecointre, Sarah Bétrian, et al.. (2021). Basics of immunotherapy for epithelial ovarian cancer. Journal of Gynecology Obstetrics and Human Reproduction. 51(2). 102283–102283. 8 indexed citations
9.
Tourneau, Christophe Le, Jean‐Pierre Delord, Nuria Kotecki, et al.. (2020). A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics and pharmacodynamics of AsiDNA, a first-in-class DNA repair inhibitor, administered intravenously in patients with advanced solid tumours. British Journal of Cancer. 123(10). 1481–1489. 5 indexed citations
10.
Brahmi, Mehdi, Hélène Vanacker, Lauriane Eberst, et al.. (2020). Therapeutic relevance of molecular screening program in patients with metastatic sarcoma: Analysis from the ProfiLER 01 trial. Translational Oncology. 13(12). 100870–100870. 8 indexed citations
11.
Aust, Stefanie, Lauriane Eberst, Olivier Trédan, et al.. (2020). Detailed overview on rare malignant ovarian tumors. Bulletin du Cancer. 107(3). 385–390. 9 indexed citations
12.
Eberst, Lauriane, Caroline Bailleux, & Thomas Bachelot. (2020). Prevention of brain metastases in human epidermal growth factor receptor 2-positive breast cancer. Current Opinion in Oncology. 32(6). 555–560. 2 indexed citations
13.
Verspoor, F.G.M., M.J.L. Mastboom, Gerjon Hannink, et al.. (2019). Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor. Scientific Reports. 9(1). 14551–14551. 46 indexed citations
14.
Eberst, Lauriane, et al.. (2019). Immune checkpoint inhibitor-based combinations: is dose escalation mandatory for phase I trials?. Annals of Oncology. 30(11). 1751–1759. 14 indexed citations
15.
Saleh, Mansoor N., Philippe A. Cassier, Lauriane Eberst, et al.. (2019). Ramucirumab plus merestinib in previously treated metastatic colorectal cancer: safety, pharmacokinetic, and preliminary efficacy findings from a Phase 1 study. Annals of Oncology. 30. iv124–iv124. 1 indexed citations
16.
Cassier, Philippe A., Christelle de la Fouchardière, Pierre Guibert, et al.. (2017). Actionable molecular alterations in advanced biliary tract carcinomas: Preliminary data from the ProfiLER program (NCT01774409). Annals of Oncology. 28. v247–v247. 1 indexed citations
17.
Eberst, Lauriane, et al.. (2017). Nouvelles perspectives dans le ciblage thérapeutique de la réparation de l’ADN. Bulletin du Cancer. 104(11). 988–998. 1 indexed citations
18.
Brahmi, Mehdi, et al.. (2017). Ciblage thérapeutique de la voie Notch en oncologie. Bulletin du Cancer. 104(10). 883–891. 5 indexed citations
19.
Griveau, Audrey, Guillaume Devailly, Lauriane Eberst, et al.. (2016). The PLA2R1-JAK2 pathway upregulates ERRα and its mitochondrial program to exert tumor-suppressive action. Oncogene. 35(38). 5033–5042. 19 indexed citations
20.
Eberst, Lauriane, Magali Morelle, M.-P. Sunyach, et al.. (2016). Focalized treatment strategy for patients with 1 to 5 breast cancer brain metastasis: a retrospective study of 70 patients treated with surgery or stereotactic radiosurgery. Annals of Oncology. 27. vi77–vi77. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by B Marmey Breakdown of academic impact, for papers by Irmgard Kronberger Breakdown of academic impact, for papers by Kyriaki Pliarchopoulou Breakdown of academic impact, for papers by Kanae Nosaka Breakdown of academic impact, for papers by K. Boye Breakdown of academic impact, for papers by James Dean Breakdown of academic impact, for papers by Huiqiang Huang Breakdown of academic impact, for papers by Séverine Tabone‐Eglinger Breakdown of academic impact, for papers by Peter Houghton Breakdown of academic impact, for papers by Vanessa Vanspauwen
Rankless by CCL
2026